Technology · Synbio & enabling tech / Genome engineering

Base editing

Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.

Maturity 4/9 Risk: medium Advanced therapies US · CN · EU Science: why it works → verified 2026-06-19 · 0 Sources (0 independent)

1 · What it gives

Base editing makes a single-nucleotide change with no double-strand break (DSB) and no indel risk: a chimeric protein fuses catalytically dead Cas9 (dCas9) or nickase nCas9 to a DNA deaminase. Cytidine editors (CBE) convert C· G to T· A; adenine editors (ABE) convert A· T to G· C. The absence of DSB rules out the large chromosomal rearrangements and karyotype chaos of classic Cas9. First ABE clinical trials showed up to 90% correction with minimal off-targets — for sickle-cell disease, beta-thalassemia, progeria.

Key platforms of base editing:

Cytidine editors (CBE): C· G to T· A (APOBEC/AID deaminases).
Adenine editors (ABE): A· T to G· C (TadA*8e, k_cat > 10 s⁻¹).
Nickase nCas9 (D10A): a single-strand nick on the unedited strand drives repair.
RNP/LNP delivery: pre-formed ribonucleoproteins or mRNA in lipid nanoparticles.

Sectoral value chain#

[gRNA design + deaminase choice] ──> [CBE/ABE expression + purification] ──> [mRNA/RNP + LNP formulation]
                                                                                       │
                                                                              (cell delivery)
                                                                                       │
                                                                                       ▼
[QC: accuracy + off-target] <─── [deep sequencing] <─── [targeted deamination]

Value chain levels#

Level	Description	Key inputs/outputs
Editor Design	gRNA choice, deaminase, narrow window (1–2 nt)	In: target. Out: editor design.
Protein Expression	E. coli producer of nCas9-deaminase (e.g. TadA*8e)	In: constructs, media. Out: lysate.
Purification	Ni-NTA + ion-exchange chromatography to >98%	In: lysate. Out: pure CBE/ABE.
sgRNA + RNP Assembly	sgRNA synthesis (OligoPilot), RNP assembly 1{:}1.2	In: protein, sgRNA. Out: RNP complex.
Delivery (ex vivo / in vivo)	MaxCyte electroporation into CD34^+ or LNP	In: RNP, cells. Out: edited cells.
Genome QC	Amplicon-seq — target change, no indels/off-target	In: cell DNA. Out: editing report.

Cross-cutting technologies of the sector:

Narrow window (narrow-window): mutant deaminases active over 1–2 nt — no bystander editing.
RNP delivery: pre-formed RNPs for short activity and minimal off-targets.
CBE+ABE tandems: dual editors for several base changes at once.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

1
Protein expression
An E. coli producer over-expresses the chimeric protein (e.g. nCas9-TadA*8e for ABE) in a fermenter.
2
Protein purificationPurification & downstream
Lysis, Ni-NTA metal-affinity + ion-exchange chromatography to >98% purity.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ ISO 9001 500 m3
“Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
Alfa Laval Sweden
✓ ISO 9001
“Here we compare the three most common options: centrifugation, filtration and coalescence.”
GenScript ProBio / Genscript China
industrial scale
“testing, including mass spectrometry and analytical high performance liquid chromatography”
HLB Genex (ex-GenoFocus) South Korea
industrial scale
“With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
3
sgRNA synthesisSynthesis & conversion
Chemical synthesis of the guide RNA with modifications on OligoPilot.
Who can do this step matched automatically
Biomason United States
industrial scale
“Enzymatic processes from microorganisms replace the need for high energy, eliminating direct emissions.”
China Everbright Environment Group China
163,050 tonnes
“Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”
Aum Enzymes / Infinita Biotech India
“2026-06-28 [BIOCATALYST LEADERSHIP: How Enzymes are Propelling India's Pharma Bio Spectrum - business - Read this story on Magzter.com — A brief mention of Aum Enzymes or Infinita …”
4
RNP assembly
ABE/CBE protein and sgRNA are mixed at 1{:}1.2 at room temperature for self-assembly.
5
Ex-vivo electroporation
RNPs are electroporated into autologous CD34^+ stem cells on MaxCyte GTx.
6
Genome QCTesting & analytics
Amplicon-seq verifies the target change and the absence of indels/off-targets before transplantation.
Who can do this step matched automatically
GenScript ProBio / Genscript China
industrial scale
“ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”

4 · Who delivers

Matched suppliers (matched automatically)

Integriculture	Japan	Equipment	active
Origin Agritech (NASDAQ: SEED)	China	Research / RTO	active
ImpacFat	Singapore	Producer	active
Acceligen	United States	Not classified	active

In the services and supply catalogue 1 · paid service

Reagents & kits

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Beam Therapeutics	🇺🇸 USA	BEAM-101 (ABE/CBE)	key ABE/CBE patents, clinical	Scaling
Prime Medicine	🇺🇸 USA	Prime+Base hybrids	precise neurodegeneration editing	Scaling
EdiGene	🇨🇳 China	domestic BE editors	haematology clinical trials	Scaling
Wenzhou Medical University	🇨🇳 China	BE for inherited blindness	prenatal editing	Research
Max Planck Institute	🇩🇪 Germany	nCas9-deaminase structural biology	thermostable deaminases	Research
Broad Institute	🇺🇸 USA	birthplace of base editing (D. Liu lab)	ultra-precise deaminases	Research

5 · Rules & route to market

United States

The US holds the key patents (David Liu lab, Harvard/Broad) and leads in the clinic.

Beam Therapeutics, Prime Medicine, FDA deep-sequencing oversight#

Beam Therapeutics: key ABE/CBE patents, BEAM-101 (sickle-cell disease).
Prime Medicine: hybrid Prime+Base platforms for neurodegeneration.
FDA: detailed deep sequencing of target loci post-therapy; delivery biosafety oversight.

European Union

The EU leads in deaminase-nCas9 structural biology and ex-vivo virus-free delivery.

Max Planck, DKFZ/DE-DK-FR, EMA long-term safety#

Max Planck Institute: nCas9-deaminase crystallography, thermostable deaminases.
DE/DK/FR labs: virus-free editor delivery into blood stem cells ex vivo.
EMA: long-term culture of edited cells before transplantation.

China

China is one of the leaders by number of Base Editing clinical trials.

EdiGene, Wenzhou Medical University, NMPA orphan-disease fast-track#

EdiGene: domestic editors, haematology clinical trials.
Wenzhou Medical University: high-precision BE for inherited blindness; prenatal editing.
NMPA: subsidies and simplified phase-1 protocols for orphan diseases.

6 · Money: tenders & grants

Tender	Greece – Biochemical analysers – ΗΛΕΚΤΡΟΝΙΚΟΣ ΑΝΟΙΚΤΟΣ ΔΙΑΓΩΝΙΣΜΟΣ ΑΝΩ ΤΩΝ ΟΡΙΩΝ ΣΕ ΕΥΡΩ ΓΙΑ ΤΗΝ ΠΡΟΜΗΘΕΙΑ … ΓΕΝΙΚΟ ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΟΓΚΟΛΟΓΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ "Ο ΑΓΙΟΣ ΣΑΒΒΑΣ" · Greece	Dec 11, 2026 56 days
Tender	Netherlands – Blood-testing reagents – Gevalideerde Totaaloplossing voor de hielprikscreening op … Rijksinstituut voor Volksgezondheid en Milieu (RIVM) · Netherlands	Nov 10, 2026 25 days

7 · Tech stack & innovations

The stack rests on evolved deaminases, nCas9 nickase and analytics.

TadA*8e (ABE deaminase):
- a super-fast evolved tRNA deaminase on single-stranded DNA, k_cat > 10 s⁻¹.
Nickase nCas9 (D10A):
- a single-strand nick on the unedited strand drives repair off the edited strand.
Analytics:
- Illumina MiSeq + Oxford Nanopore GridION (long-deletion detection); Benchling for sgRNA design.